Cancer Predisposition | CHOP Research Institute

Cancer Predisposition

Published on
Jan 27, 2023
By studying the molecular basis of pediatric thyroid cancer, Dr. Franco seeks to improve outcomes and quality of life for patients.
Published on
Jan 3, 2022
Congratulations to Garrett Brodeur, MD, recipient of the American Society of Pediatric Hematology/Oncology Distinguished Career Award.
Published on
Aug 6, 2021
This week’s research news features Dr. Audrey Odom John and her discovery of six breath compounds that could lead to a COVID breathalyzer for kids.

The Kalish Lab studies the genetic and epigenetic causes of growth disorders and cancer predisposition. The lab focuses on studying Beckwith-Wiedemann syndrome (BWS), the most common epigenetic and cancer predisposition disorder, and also runs the BWS registry and biorepository.

Research in the Brodeur Lab focuses on two main areas: nanoparticle drug delivery and cancer predisposition. Nanomedicines allow the delivery of much more drug to the tumor and much less to the patient.

Dr. Franco researches the molecular basis of the differences between pediatric and adult onset thyroid cancer. She aims to understand how the tumor microenvironment impacts disease progression and response to therapy.

francoa1 [at]

Facilitating interaction between Beckwith-Wiedemann Syndrome (BWS) clinical experts, scientists, patient advocates, and BWS families to improve diagnosis, quality of care, and knowledge about BWS.

Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.

brodeur [at]